Physician profile
Jane E Hartline
NPI 1548390768
$5,017.96
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,785 · 2020: $959 · 2021: $734 · 2022: $943 · 2023: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $605.85 | 2019-2023 | Prolia, Evenity, Otezla |
| Pfizer INC. | $532.89 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $424.36 | 2019-2023 | Farxiga |
| Abbvie INC. | $361.60 | 2019-2023 | |
| Glaxosmithkline, LLC. | $344.78 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $254.35 | 2019-2021 | |
| Medicure Pharma INC. | $229.51 | 2020-2021 | |
| Novo Nordisk INC | $210.18 | 2019-2023 | Ozempic, Rybelsus |
| Radius Health, INC. | $178.41 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $174.47 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.19 | 2019-2022 | |
| Lilly USA, LLC | $157.01 | 2019-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.46 | 2019-2023 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $145.01 | 2019-2023 | Vaxneuvance, Gardasil 9 |
| Abbott Laboratories | $134.37 | 2022-2023 | Freestyle Libre 2 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $120.85 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $114.78 | 2021-2023 | |
| Sanofi Pasteur INC. | $105.03 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $99.81 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $89.50 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $65.57 | 2019 | |
| Allergan, INC. | $65.17 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $51.21 | 2022-2023 | Austedo Xr, Ajovy |
| Biohaven Pharmaceuticals, INC. | $43.91 | 2021 | |
| Eisai INC. | $31.84 | 2021 | |
| Nestle Healthcare Nutrition INC. | $26.29 | 2022-2023 | |
| Almatica Pharma LLC | $20.34 | 2023 | Loreev Xr, Sertraline Hcl |
| Exact Sciences Corporation | $18.95 | 2023 | Cologuard Collection Kit |
| Averitas Pharma INC. | $17.83 | 2023 | Qutenza |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.00 | 2022 | |
| Mylan Specialty L.P. | $15.25 | 2021 | |
| Nevro Corp. | $13.70 | 2023 | Senza |
| Dexcom, INC. | $12.28 | 2021 | |
| Amneal Pharmaceuticals LLC | $12.04 | 2020 | |
| Phadia US INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Hartline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.